Heron Therapeutics, Inc. Overview
Pro stress-test →Heron is a commercial-stage biotech focused on acute care and oncology, selling four FDA-approved drugs: ZYNRELEF, APONVIE, CINVANTI and SUSTOL, all built on proprietary drug-delivery science. The company focuses on developing and commercializing innovative, extended-release drug therapies using its proprietary biochronomer platform, with main products addressing postoperative pain and chemotherapy-induced nausea and vomiting.
Strategic Profile
Pro stress-test →The company reported $154.9 million net revenue for 2025, driven by a 65.1% year-over-year rise in its Acute Care franchise. The company issued 2026 guidance of $173–$183 million net revenue and $10–$20 million adjusted EBITDA. Heron has built a robust intellectual property portfolio around its biochronomer technology and product formulations, providing a strategic barrier against competition.
Competitive Landscape
Pro stress-test →Heron operates in a highly competitive industry, facing competition from both large pharmaceutical companies and smaller biotech firms including Pacira BioSciences (known for EXPAREL), Eli Lilly (strong in oncology), Amgen (cancer therapies), and Helsinn Group (cancer supportive care). Heron differentiates itself through its innovative drug delivery technologies and focus on addressing unmet medical needs.
Industry Context
Heron Therapeutics, Inc. operates in Biotechnology - Specialty Pharmaceuticals (Acute Care & Oncology).
Key facts
Founded: 1983 · Headquarters: Cary, US · Employees: 128 · Revenue: $154.9M (2025) · Market cap: N/A